BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Afinitor everolimus regulatory update

The U.K.'s NICE said it received appeals from Novartis and charity organization Kidney Cancer U.K. against a second final appraisal determination (FAD) recommending against use of the pharma's Afinitor everolimus for second-line treatment of advanced renal cell carcinoma (RCC). NICE...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >